从困惑到明晰：银屑病慢病管理的探索与实践

doi:10.35541/cjd.20240014

Abstract

Abstract: 【Abstract】 In recent years, there has been continuous development in the management strategies for psoriasis, yet many issues remain to be "resolved" and "explained". This review focuses on the latest management goals of psoriasis, the benefits of early medical intervention, patient-centered treatment plans, the selection and transition of biologics, management of relapse, and unmet needs, aiming to provide a reference for patients and healthcare professionals.

Key words: Psoriasis, Arthritis, psoriatic, Biological agents, Disease management, Recurrence

Zheng Yuxin, Zheng Min. From confusion to clarity: exploration and practice in the chronic disease management of psoriasis[J]. Chinese Journal of Dermatology,2024,e20240014. doi:10.35541/cjd.20240014

References ［46］

［1］	中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2023版）［J］. 中华皮肤科杂志, 2023,56（7）:573⁃625. doi: 10.35541/cjd.20220839.
［2］	Ghoreschi K, Balato A, Enerbäck C, et al. Therapeutics targeting the IL⁃23 and IL⁃17 pathway in psoriasis［J］. Lancet, 2021,397（10275）:754⁃766. doi: 10.1016/S0140⁃6736（21）00184⁃7.
［3］	Campanati A, Marani A, Martina E, et al. Psoriasis as an immune⁃mediated and inflammatory systemic disease: from pathophysiology to novel therapeutic approaches［J］. Biomedicines, 2021,9（11）:1511. doi: 10.3390/biomedicines9111511.
［4］	Mrowietz U, Steinz K, Gerdes S. Psoriasis: to treat or to manage?［J］. Exp Dermatol, 2014,23（10）:705⁃709. doi: 10.1111/exd. 12437.
［5］	中华医学会皮肤性病学分会银屑病专业委员会. 银屑病生物制剂达标治疗专家共识［J］. 中华皮肤科杂志, 2023,56（3）:191⁃203. doi: 10.35541/cjd.20220652.
［6］	Wang K, Zhao Y, Cao X. Global burden and future trends in psoriasis epidemiology: insights from the global burden of disease study 2019 and predictions to 2030［J］. Arch Dermatol Res, 2024,316（4）:114. doi: 10.1007/s00403⁃024⁃02846⁃z.
［7］	Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council［J］. J Am Acad Dermatol, 2020,82（1）:117⁃122. doi: 10.1016/j.jaad.2019.08.026.
［8］	Krueger JG, Wharton KA Jr, Schlitt T, et al. IL⁃17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis［J］. J Allergy Clin Immunol, 2019,144（3）:750⁃763. doi: 10.1016/j.jaci.2019.04.029.
［9］	Schäkel K, Reich K, Asadullah K, et al. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance （'clinical super response'）: week 28 results from the ongoing phaseⅢb randomized, double⁃blind, parallel⁃group, GUIDE study［J］. J Eur Acad Dermatol Venereol, 2023,37（10）:2016⁃2027. doi: 10.1111/jdv.19236.
［10］	Huang YW, Tsai TF. Remission duration and long⁃term outcomes in patients with moderate⁃to⁃severe psoriasis treated by biologics or tofacitinib in controlled clinical trials: a 15⁃year single⁃center experience［J］. Dermatol Ther （Heidelb）, 2019,9（3）:553⁃569. doi: 10.1007/s13555⁃019⁃0310⁃5.
［11］	Kampylafka E, Simon D, d'Oliveira I, et al. Disease interception with interleukin⁃17 inhibition in high⁃risk psoriasis patients with subclinical joint inflammation⁃data from the prospective IVEPSA study［J］. Arthritis Res Ther, 2019,21（1）:178. doi: 10.1186/s13075⁃019⁃1957⁃0.
［12］	von Stebut E, Reich K, Thaçi D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks［J］. J Invest Dermatol, 2019,139（5）:1054⁃1062. doi: 10.1016/j.jid.2018. 10.042.
［13］	Eyerich K, Krueger J, Stahle M, et al. An international Delphi consensus to define a clinically appropriate definition of disease modification for plaque psoriasis［J］. J Eur Acad Dermatol Venereol, 2024,38（5）:e424⁃e427. doi: 10.1111/jdv.19652.
［14］	Iversen L, Eidsmo L, Austad J, et al. Secukinumab treatment in new⁃onset psoriasis: aiming to understand the potential for disease modification ⁃ rationale and design of the randomized, multicenter STEPIn study［J］. J Eur Acad Dermatol Venereol, 2018,32（11）:1930⁃1939. doi: 10.1111/jdv.14979.
［15］	Iversen L, Conrad C, Eidsmo L, et al. Secukinumab demonstrates superiority over narrow⁃band ultraviolet B phototherapy in new⁃onset moderate to severe plaque psoriasis patients: week 52 results from the STEPIn study［J］. J Eur Acad Dermatol Venereol, 2023,37（5）:1004⁃1016. doi: 10.1111/jdv.18846.
［16］	中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物制剂治疗指南（2021）［J］. 中华皮肤科杂志, 2021,54（12）:1033⁃1047. doi: 10.35541/cjd.20210643.
［17］	Balakirski G, Gerdes S, Beissert S, et al. Therapy of psoriasis during pregnancy and breast⁃feeding［J］. J Dtsch Dermatol Ges, 2022,20（5）:653⁃683. doi: 10.1111/ddg.14789.
［18］	Griffiths C, Armstrong AW, Gudjonsson JE, et al. Psoriasis［J］. Lancet, 2021,397（10281）:1301⁃1315. doi: 10.1016/S0140⁃6736（20）32549⁃6.
［19］	Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate⁃to⁃severe psoriasis （ECLIPSE）: results from a phase 3, randomised controlled trial［J］. Lancet, 2019,394（10201）:831⁃839. doi: 10.1016/S0140⁃6736（19）31773⁃8.
［20］	Cai L, Zhang JZ, Yao X, et al. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis［J］. Chin Med J （Engl）, 2020,133（22）:2665⁃2673. doi: 10.1097/CM9.0000000 000001163.
［21］	Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti⁃interleukin⁃23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phaseⅢ, double⁃blinded, placebo⁃ and active comparator⁃controlled VOYAGE 1 trial［J］. J Am Acad Dermatol, 2017,76（3）:405⁃417. doi: 10.1016/j.jaad.2016.11.041.
［22］	Schett G, McInnes IB, Neurath MF. Reframing immune⁃mediated inflammatory diseases through signature cytokine hubs［J］. N Engl J Med, 2021,385（7）:628⁃639. doi: 10.1056/NEJMra1909094.
［23］	Blair HA. Secukinumab: a review in psoriatic arthritis［J］. Drugs, 2021,81（4）:483⁃494. doi: 10.1007/s40265⁃021⁃01476⁃3.
［24］	Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis （GRAPPA）: updated treatment recommendations for psoriatic arthritis 2021［J］. Nat Rev Rheumatol, 2022,18（8）:465⁃479. doi: 10.1038/s41584⁃022⁃00798⁃0.
［25］	Singla S, Putman M, Liew J, et al. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study［J］. Lancet Rheumatol, 2023,5（4）:e200⁃e207. doi: 10.1016/S2665⁃9913（23）00034⁃6.
［26］	Morita A, Tsai TF, Yee E, et al. Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: results from the randomized, double⁃blind, placebo⁃controlled Effisayil™ 1 study［J］. J Dermatol, 2023,50（2）:183⁃194. doi: 10.1111/1346⁃8138.16609.
［27］	Rosi E, Fastame MT, Di Cesare A, et al. Targeting IL⁃17A for the treatment of pustular psoriasis: a comprehensive review［J］. Expert Opin Biol Ther, 2022,22（12）:1475⁃1487. doi: 10.1080/14712598.2022.2116978.
［28］	Megna M, Camela E, Ruggiero A, et al. Use of biological therapies for the management of pustular psoriasis: a new era?［J］. Clin Cosmet Investig Dermatol, 2023,16:1677⁃1690. doi: 10.2147/CCID.S407812.
［29］	中国医师协会皮肤科医师分会，中国中西医结合学会皮肤性病学分会. 红皮病型银屑病诊疗中国专家共识（2024版）［J］．中华皮肤科杂志，2024,57（5）:409⁃417. doi: 10.35541/cjd. 20230570.
［30］	Potestio L, Camela E, Cacciapuoti S, et al. Biologics for the management of erythrodermic psoriasis: an updated review［J］. Clin Cosmet Investig Dermatol, 2023,16:2045⁃2059. doi: 10. 2147/CCID.S407813.
［31］	周颖, 沙扬, 于浈, 等. 红皮病型银屑病治疗的研究进展［J］. 中国医学前沿杂志（电子版）, 2023,15（11）:21⁃28. doi: 10. 12037/YXQY.2023.11⁃04.
［32］	Ruiz⁃Villaverde R, Rodriguez⁃Fernandez⁃Freire L, Armario⁃Hita JC, et al. Guselkumab as a switching strategy after anti⁃TNFα, anti⁃IL17, or anti⁃IL12/23 therapies in moderate⁃to⁃severe psoriasis［J］. Dermatol Ther, 2022,35（10）:e15760. doi: 10.1111/dth.15760.
［33］	Megna M, Potestio L, Ruggiero A, et al. Guselkumab is efficacious and safe in psoriasis patients who failed anti⁃IL17: a 52⁃week real⁃life study［J］. J Dermatolog Treat, 2022,33（5）:2560⁃2564. doi: 10.1080/09546634.2022.2036674.
［34］	Liu S, He M, Jiang J, et al. Triggers for the onset and recurrence of psoriasis: a review and update［J］. Cell Commun Signal, 2024,22（1）:108. doi: 10.1186/s12964⁃023⁃01381⁃0.
［35］	Wang W, Qiu Y, Zhao F, et al. Poor medication adherence in patients with psoriasis and a successful intervention［J］. J Dermatolog Treat, 2019,30（6）:525⁃528. doi: 10.1080/09546634. 2018.1476652.
［36］	Blauvelt A, Reich K, Warren RB, et al. Secukinumab re⁃initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis［J］. Br J Dermatol, 2017,177（3）:879⁃881. doi: 10.1111/bjd.15656.
［37］	Gordon KB, Armstrong AW, Foley P, et al. Guselkumab efficacy after withdrawal is associated with suppression of serum IL⁃23⁃regulated IL⁃17 and IL⁃22 in psoriasis: VOYAGE 2 study［J］. J Invest Dermatol, 2019,139（12）:2437⁃2446.e1. doi: 10.1016/j.jid.2019.05.016.
［38］	McInnes IB, Gravallese EM. Immune⁃mediated inflammatory disease therapeutics: past, present and future［J］. Nat Rev Immunol, 2021,21（10）:680⁃686. doi: 10.1038/s41577⁃021⁃00603⁃1.
［39］	Tang X, Li Q, Zhou Y, et al. Predictive factors of atopic⁃like dermatitis induced by IL⁃17A inhibitors in patients with psoriasis: a 2⁃year follow⁃up study［J］. J Eur Acad Dermatol Venereol, 2023,37（12）:2509⁃2516. doi: 10.1111/jdv.19394.
［40］	van der Schoot LS, van den Reek J. Data⁃driven prediction of biologic treatment responses in psoriasis: steps towards precision medicine［J］. Br J Dermatol, 2021,185（4）:698⁃699. doi: 10. 1111/bjd.20625.
［41］	Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment⁃as⁃needed versus fixed⁃interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double⁃blind, noninferiority trial （SCULPTURE）［J］. J Am Acad Dermatol, 2015,73（1）:27⁃36.e1. doi: 10.1016/j.jaad.2015.04.011.
［42］	Blauvelt A, Ferris LK, Yamauchi PS, et al. Extension of ustekinumab maintenance dosing interval in moderate⁃to⁃severe psoriasis: results of a phaseⅢb, randomized, double⁃blinded, active⁃controlled, multicentre study （PSTELLAR）［J］. Br J Dermatol, 2017,177（6）:1552⁃1561. doi: 10.1111/bjd.15722.
［43］	Ye LR, Yan BX, Chen XY, et al. Extended dosing intervals of ixekizumab for psoriasis: a single⁃center, uncontrolled, prospective study［J］. J Am Acad Dermatol, 2022,86（6）:1348⁃1350. doi: 10.1016/j.jaad.2021.04.093.
［44］	Chen XB, Zheng YX, Ye LR, et al. Gradually increasing the dosing interval of secukinumab for moderate to severe plaque psoriasis: a single⁃center, uncontrolled, prospective study in 36 weeks［J］. Dermatol Ther, 2022,35（12）:e15911. doi: 10.1111/dth.15911.
［45］	Zheng YX, Zheng M. A multidisciplinary team for the diagnosis and management of psoriatic arthritis［J］. Chin Med J （Engl）, 2021,134（12）:1387⁃1389. doi: 10.1097/CM9.0000000000001588.
［46］	Liu Z, Wang X, Ma Y, et al. Artificial intelligence in psoriasis: where we are and where we are going［J］. Exp Dermatol, 2023,32（11）:1884⁃1899. doi: 10.1111/exd.14938.

[1]	Committee on Psoriasis, Chinese Society of Dermatology. Expert proposal on apremilast for the treatment of psoriasis （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(5): 416-424.
[2]	China Dermatologist Association, Treatment Group, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, National Clinical Research Center for Dermatologic and Immunologic Diseases, Rare Skin Diseases Committee, China Alliance for Rare Diseases. Diagnosis and treatment of bullous pemphigoid: an expert consensus statement （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(5): 405-415.
[3]	Li Ziyu, Lu Yan. Paying attention to severe skin diseases after COVID-19 [J]. Chinese Journal of Dermatology, 2025, 58(4): 378-383.
[4]	Group on Pediatric Dermatology, China Dermatologist Association, Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on the diagnosis and treatment of pediatric pustular psoriasis in China （2025 version） [J]. Chinese Journal of Dermatology, 2025, 58(4): 297-306.
[5]	He Chunxia, Jin Hongzhong . Principles, current status, challenges and perspectives in the diagnosis and treatment of critical dermatological emergencies [J]. Chinese Journal of Dermatology, 2025, 58(4): 307-314.
[6]	Mu Kui, Guo Hui, Wen Haiquan, Long Hai, Liu Yu, Luo Shuaihantian, Huang Xin, Zhou Xingyu, Xiao Rong, Li Yaping. Efficacy and safety analysis of combined telitacicept in 25 patients with systemic lupus erythematosus based on standard therapy [J]. Chinese Journal of Dermatology, 2025, 58(4): 322-327.
[7]	Wang Caixia, Xu Fan, Shi Jing, Zhu Hailian, Lu Guiling, Wang Hongmei. Efficacy and safety of omalizumab and dupilumab for the treatment of bullous pemphigoid: a systematic review [J]. Chinese Journal of Dermatology, 2025, 0(3): 20220929-e0220929.
[8]	Li Xiuzhen, Xu Xiulian. Effects of interleukin-23 inhibitors on psoriasis comorbidities [J]. Chinese Journal of Dermatology, 2025, 58(3): 268-272.
[9]	Lianghong Chen Yan SUN Jing-Yu WANG. Benvitimod for the treatment of dermatoses [J]. Chinese Journal of Dermatology, 2025, 58(3): 266-268.
[10]	Xu Zhuohong, Hu Yu, Gu Heng. Role of mesenchymal stem cell-derived exosomes in skin diseases [J]. Chinese Journal of Dermatology, 2025, 0(3): 20220881-e20220881.
[11]	Ye Hui, Deng Shilin, Liang Jingyao, Zhang Xibao. Correlations between the control of atopic dermatitis recurrence and tissue-resident memory T cells [J]. Chinese Journal of Dermatology, 2025, 0(3): 20240192-e20240192.
[12]	Wang Wenqiu, Li Chengxin, Wang Rui. Biologics for the treatment of psoriasis relapse: current status [J]. Chinese Journal of Dermatology, 2025, 0(3): 20230301-e20230301.
[13]	Zhang Xiaoxu, Luo Suju. Efficacy and safety of upadacitinib in the treatment of six cases of palmoplantar pustulosis [J]. Chinese Journal of Dermatology, 2025, 0(2): 20230772-e20230772.
[14]	Jin Lan, Qiu Yun, Wang Weijia, Kang Xiaojing, Ding Yuan. Clinical efficacy and safety of biological agents in the treatment of moderate-to-severe psoriasis in 124 elderly patients: a retrospective analysis [J]. Chinese Journal of Dermatology, 2025, 58(1): 47-52.
[15]	Wang Bo, Zheng Jie. Considerations in the treatment of elderly patients with psoriasis and atopic dermatitis using biologics and small-molecule drugs [J]. Chinese Journal of Dermatology, 2025, 58(1): 72-75.

From confusion to clarity: exploration and practice in the chronic disease management of psoriasis

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［46］

Related Articles 15

Metrics

Comments

Recommended 10